Rhumbline Advisers Sells 3,905 Shares of Avanos Medical, Inc. (NYSE:AVNS)

Rhumbline Advisers reduced its stake in Avanos Medical, Inc. (NYSE:AVNS) by 2.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 148,705 shares of the company’s stock after selling 3,905 shares during the period. Rhumbline Advisers owned 0.32% of Avanos Medical worth $2,962,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. EntryPoint Capital LLC increased its position in shares of Avanos Medical by 97.6% during the first quarter. EntryPoint Capital LLC now owns 5,601 shares of the company’s stock worth $112,000 after acquiring an additional 2,766 shares in the last quarter. Janney Montgomery Scott LLC increased its position in shares of Avanos Medical by 19.1% during the first quarter. Janney Montgomery Scott LLC now owns 13,010 shares of the company’s stock worth $259,000 after acquiring an additional 2,082 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Avanos Medical during the fourth quarter worth about $327,000. Pitcairn Co. increased its position in shares of Avanos Medical by 11.2% during the first quarter. Pitcairn Co. now owns 15,940 shares of the company’s stock worth $317,000 after acquiring an additional 1,606 shares in the last quarter. Finally, Natixis Advisors LLC grew its position in Avanos Medical by 19.5% in the 2nd quarter. Natixis Advisors LLC now owns 18,878 shares of the company’s stock worth $376,000 after purchasing an additional 3,077 shares in the last quarter. 95.17% of the stock is owned by institutional investors.

Avanos Medical Trading Down 0.2 %

Shares of AVNS stock opened at $24.15 on Wednesday. Avanos Medical, Inc. has a 52-week low of $17.24 and a 52-week high of $24.89. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.49 and a current ratio of 2.28. The company has a 50-day simple moving average of $23.09 and a two-hundred day simple moving average of $20.75. The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -18.16 and a beta of 0.91.

Avanos Medical (NYSE:AVNS) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.05. Avanos Medical had a net margin of 1.13% and a return on equity of 4.48%. The business had revenue of $171.70 million during the quarter, compared to the consensus estimate of $170.67 million. During the same period in the prior year, the firm posted $0.24 EPS. The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. Research analysts anticipate that Avanos Medical, Inc. will post 1.39 EPS for the current fiscal year.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.